2026-09-28

Kodiak Sciences (KOD) Stock Soars 160% on Phase 3 DAYBREAK Win - A Comeback From 2023's Wet AMD Setback

Written & reviewed by the TradeSmrt editorial team · 2026-09-28

In this article

What Happened
Why the Market Reacted This Hard - The Six-Month Dosing Story
The 2023 Setback, and Today's Reversal
What to Take Away From This
FAQ
Sources

What Happened

Kodiak Sciences (NASDAQ: KOD) stock exploded higher in Monday, September 28 premarket trading, and the rally carried into the regular session. Shares that closed the prior day at $32.35 spiked as high as roughly $90 at one point, with some intraday readings putting the gain above 160%. Trading through the morning session settled the stock closer to $72.93, still up about 125% on the day. Either way you measure it, this small-cap biotech more than doubled its market capitalization in a single trading day - the kind of move that only happens a handful of times a year on Nasdaq, and a textbook reminder of how binary a single clinical readout can be for a clinical-stage drugmaker.

The catalyst was topline data from Kodiak's Phase 3 DAYBREAK trial, released before Monday's open. DAYBREAK is a large, late-stage study in patients with wet age-related macular degeneration (wet AMD), testing two of the company's drug candidates head to head: Zenkuda (tarcocimab tedromer) and a newer molecule called tabirafusp-ted. Both hit their marks. Zenkuda's primary efficacy endpoint came in with a p-value of 0.0007 - a highly statistically significant result - and the drug demonstrated non-inferiority in one-year vision gains compared with Regeneron's Eylea (aflibercept), the current standard of care. Tabirafusp-ted also cleared its own vision-related primary endpoint (p=0.0036) and hit a key secondary endpoint measuring anatomical retinal improvement.

Why the Market Reacted This Hard - The Six-Month Dosing Story

The scale of the reaction has less to do with the trial simply "succeeding" and more to do with what that success implies commercially. Zenkuda's ocular half-life runs about 20 days - roughly three times longer than currently approved anti-VEGF (vascular endothelial growth factor) therapies. Building on that durability, Kodiak reported that 54% of DAYBREAK patients were able to stay on a six-month dosing schedule. That matters enormously in wet AMD, a chronic condition that overwhelmingly affects elderly patients and requires injections directly into the eye - a procedure that's a real burden on both patients and caregivers every time they have to show up for it. Dosing-interval extension has been the central competitive battleground in this drug class for years: Eylea is dosed every eight weeks, the higher-dose Eylea HD stretches that to every 12-16 weeks, and Roche's Vabysmo (faricimab) can extend to every 16 weeks for some patients. If Zenkuda reaches the market with a genuine twice-a-year profile intact, it would represent a meaningful convenience edge over anything currently approved.

Kodiak says DAYBREAK is now the fifth positive Phase 3 readout supporting Zenkuda, and the company plans to file a Biologics License Application (BLA) with the FDA in the fourth quarter of 2026. Standard FDA review typically runs around ten months from filing, which puts a realistic launch window sometime in 2027 if the review goes smoothly. The fact that investors bid the stock up this aggressively well before any regulatory decision is a familiar biotech pattern: the stock tends to move hardest at the data readout, with the actual approval and commercial launch arriving - and getting priced in - much later.

The 2023 Setback, and Today's Reversal

To really understand today's move, it helps to know Kodiak's recent history. Back in July 2023, the company released Phase 3 results for the same tarcocimab tedromer molecule in a different indication - diabetic macular edema (DME) - through the GLEAM and GLIMMER trials. Those studies missed their primary efficacy endpoints, driven largely by an unexpected spike in cataract-related adverse events (19% in the tarcocimab arm versus 9% on aflibercept). The stock cratered on that news and Kodiak spent years afterward as something of a broken story, with tarcocimab's commercial prospects widely doubted. What often gets lost in that narrative, though, is that two other Phase 3 trials read out around the same time and succeeded: DAYLIGHT, in wet AMD, and BEACON, in retinal vein occlusion (RVO). In other words, Kodiak's pipeline had a mixed record by indication - it wasn't a company whose science had failed across the board, even if that's how the market treated it for a while.

Monday's DAYBREAK data effectively reconfirms that earlier wet AMD success with a larger, more definitive trial. A big part of why the market re-rated the stock by more than double in a single session is that KOD had been trading as if the 2023 disappointment still defined the whole company. Consider that going into Monday, the average analyst price target sat at just $35.43 (ranging from $14 to $80) across seven analysts covering the stock - barely above Monday's opening price of $32.35. That gap tells you Wall Street itself hadn't fully priced in the possibility of a DAYBREAK win, which is exactly the kind of expectations mismatch that produces an outsized one-day move once new data arrives.

None of this makes the road ahead automatic, though. Wet AMD is a crowded, mature market dominated by Regeneron (Eylea, Eylea HD) and Roche (Vabysmo), with a long list of additional players - Novartis, Bayer, AbbVie, Boehringer Ingelheim, Amgen, and Samsung Bioepis among them - also active in retinal disease. Winning a clinical trial on paper doesn't automatically translate into market share; actual prescribing habits, insurance reimbursement dynamics, and real-world safety data will all shape how quickly (or slowly) physicians switch patients over. There's also ordinary regulatory risk between now and any potential approval, including the possibility of additional FDA information requests or manufacturing-site inspections that could push back the timeline.

What to Take Away From This

A single clinical readout can more than double a biotech's market cap in one day. Small-cap biotechs like Kodiak, with value concentrated in a handful of pipeline assets, live and die by their Phase 3 data releases. If you hold or are considering a stock like this, treat the trial-readout calendar itself as the single biggest source of near-term volatility risk.
A past failure in one indication doesn't mean the whole pipeline failed. Kodiak missed in diabetic macular edema in 2023 but succeeded in wet AMD and retinal vein occlusion around the same time. Judging a drug candidate indication-by-indication, rather than writing off a company after one bad headline, can help you avoid missing a legitimate turnaround.
Dosing-interval extension is an unusually powerful differentiator in chronic-disease markets. In treatment areas where the delivery method itself - like an eye injection - is the real burden, convenience can matter as much as raw efficacy in determining market share. When evaluating a new drug's competitive position, check the dosing schedule alongside the efficacy data, not efficacy alone.
Watch the gap between analyst price targets and the current stock price heading into a binary catalyst. When targets sit close to the current price right before a major trial readout, it can signal that even professional analysts weren't confident which way the data would break. In that situation, it's worth reasoning through both the upside and downside scenarios yourself rather than anchoring too heavily on any single price target.

FAQ

What does Kodiak Sciences actually do?

Kodiak Sciences is a California-based clinical-stage biotech that has built a proprietary technology platform designed to keep antibody drugs active in the eye for longer periods. Its lead candidate, tarcocimab tedromer (branded Zenkuda), has been studied across multiple retinal disease indications, including wet AMD, diabetic macular edema, and retinal vein occlusion.

If Zenkuda gets approved, when could patients actually access it?

Kodiak plans to file its Biologics License Application with the FDA in the fourth quarter of 2026. Standard FDA review typically takes around ten months, which would put a plausible approval and launch window somewhere in late 2027 or early 2028 if everything proceeds smoothly. That's a projection based on typical review timelines, not a guarantee - the FDA process can still shift the schedule.

Is Zenkuda definitively better than Eylea or Vabysmo?

Not yet, and that's an important distinction. DAYBREAK demonstrated non-inferiority against Eylea - meaning comparable efficacy - not superiority. Zenkuda's main competitive edge appears to be its extended, roughly six-month dosing interval rather than superior vision outcomes. Whether that convenience advantage actually translates into meaningful market share once Zenkuda reaches physicians and patients remains to be seen post-approval.

Could this rally spill over into other biotech stocks?

Direct spillover is likely limited, but the sentiment effect could be real. Kodiak's move is a fresh reminder that a beaten-down, small-cap biotech can more than double in a day on a single positive Phase 3 readout, and that pattern tends to draw renewed investor attention toward other ophthalmology and retinal-disease drug developers with their own late-stage trials on the calendar.

Sources

This article is an original synthesis and analysis based on the reporting below, not a reproduction of the original articles. Please verify the latest figures and details directly with the source reporting.

⚠️ This article is for informational purposes only and does not constitute investment advice. Market conditions change constantly - always verify the latest information before making investment decisions.